ATS 2019 Virtual Final Program

9:39 Weight Loss Strategies in Kids and Adolescents and the Impact on OSA: From Lifestyle Intervention to Bariatric Surgery N. Simakajornboon, MD, Cincinnati, OH 10:03 What Is the Real Impact of Lifestyle Intervention and Anti-Obesity Drugs on OSA Severity and Intermediary Outcomes in Adults? M.T. Naughton, MD, ATSF, Prahran, Australia 10:27 Efficacy and Safety of Bariatric Interventions in Adults with OSA and Obesity Hypoventilation Syndrome S.R. Patel, MD, Pittsburgh, PA 10:51 Sleep Extension: Can We Improve Weight and Metabolic Profile in Sleep-Deprived Patients? E. Tasali, MD, Chicago, IL BASIC • TRANSLATIONAL SCIENTIFIC SYMPOSIUM CME Credits Available: 2 C11 FUTURE DIRECTIONS IN PAH RESEARCH: A PRO/CON DEBATE Assembly on Pulmonary Circulation 9:15 a.m. - 11:15 a.m. KBHCCD Room C155-C156 (Level 1) Target Audience Basic, translational and clinical researchers, clinicians (adult and pediatrics) interested in pulmonary vascular disease and right heart failure Objectives At the conclusion of this session, the participant will be able to: • critically evaluate whether the right ventricle should be a therapeutic target in PAH or whether our research should rather focus on reversing the pulmonary vascular disease • summarize the pros and cons of animal models in PAH • learn about the importance of genetics in PAH- will be able to more appropriately discuss the values as well as the false promises of precision medicine in PAH This session will debate the future focus of research in pulmonary arterial hypertension (PAH). By employing a pro/con debate style, this session will critically evaluate opposing views of the most promising research directions with the ultimate goal to reach a consensus how best to improve pulmonary vascular disease and and right heart failure. Chairing: E.F. Spiekerkoetter, MD, Palo Alto, CA S.S. Pullamsetti, PhD, Bad Nauheim Hessen, Germany W. Kuebler, MD, Berlin, Germany 9:15 PRO: The RV Should Be a Therapeutic Target in PAH F. De Man, PhD, Amsterdam, Netherlands 9:30 CON: The RV Should NOT Be a Therapeutic Target in PAH P.M. Hassoun, MD, Baltimore, MD 9:45 PRO: The Discovery of Novel PAH Disease Genes Will Help Us Understand AND Treat PAH W.C. Nichols, PhD, Cincinnati, OH 10:00 CON: The Discovery of Novel PAH Disease Genes Will NOT Help Us Understand AND Treat PAH M. Humbert, MD, PhD, Bicetre, France 10:15 PRO: PH Animal Models Are Still Crucial for Understanding PH Development, Identifying Novel Treatment Targets and Testing Potential Therapies A. Hemnes, MD, ATSF, Nashville, TN 10:30 CON: PH Animal Models Are NOT Crucial for Understanding PH Development, Identifying Novel Treatment Targets and Testing Potential Therapies H. Olschewski, MD, Graz, Austria 10:45 PRO: Precision Medicine is Needed to Tailor the Correct PAH Therapy for the Correct Patient J. Leopold, MD, Boston, MA 11:00 CON: Precision Medicine is NOT Needed to Find Beneficial Therapies for PAH Patients - I Am a Lumper Not a Splitter S.M. Kawut, MD, MS, Philadelphia, PA This session and the International Conference are supported by an educational grant from Bayer US. All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests. BASIC • TRANSLATIONAL SCIENTIFIC SYMPOSIUM CME Credits Available: 2 C12 MACROPHAGES: LINEAGE, DIVERSITY, AND LUNG DISEASE Assemblies on Respiratory Cell and Molecular Biology; Allergy, Immunology and Inflammation; Environmental, Occupational and Population Health; Pulmonary Infections and Tuberculosis 9:15 a.m. - 11:15 a.m. KBHCCD Ballroom D One (Level 3) Target Audience Basic and translational researchers, trainees interested in understanding the latest approaches and roles of macrophages in development and disease Objectives At the conclusion of this session, the participant will be able to: • understand the concept of macrophage lineage tracing; • understand how the microenvironment determines function and phenotype in lung macrophages; • define the contributions of alveolar macrophages to a spectrum of lung diseases. This session will focus on lung macrophage diversity and lineage in the context of a spectrum of lung diseases including acute lung injury, asthma, cystic fibrosis, pulmonary alveolar proteinosis, and infections. Chairing: W.J. Janssen, MD, Denver, CO E. Plosa, MD, Nashville, TN A. Misharin, MD, PhD, Chicago, IL S.M. Cloonan, PhD, New York, NY ATS 2019 • Dallas, TX 226 TUESDAY • MAY 21